
Source: businesswire | Published on: Monday, 30 December 2024
DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: AstraZeneca Plc 2024" company profile has been added to ResearchAndMarkets.com's offering.
The report provides insights into company's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
AstraZeneca Plc is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors, and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa, and Australasia.
The report provides information and insights into AstraZeneca's tech activities, including:
Reasons to Buy
Key Topics Covered:
For more information about this company profile visit https://www.researchandmarkets.com/r/q84yg9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.